Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer

All-Comers Approach Disappoints

Metastatic prostate cancer continues to evade the checkpoint inhibitor class but Merck is not giving up on an area where overall survival remains limited.

Merck 1200
Merck and AstraZeneca's partnership has been successful but metastatic prostate cancer has again proven resistant to combination therapy • Source: Alamy

Merck & Co and AstraZeneca are to halt a Phase III study of cancer blockbusters Keytruda and Lynparza as a third-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after the combination failed to show benefits to patients.

The result is a rare setback for Keytruda and Lynparza, which have grown steadily to lead their respective PD-1/PD-L1 and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category